Form 4: Neogenomics Director Acquires Shares and Stock Options
SEC Form 4 Filing
Director David Brian Perez reports acquisition of Neogenomics stock options and disposition of common stock.
Summary
- On June 1, 2024, Director David Brian Perez acquired 8,672 stock options at an exercise price of $13.71, exercisable from June 1, 2025, and expiring on June 1, 2034.
- Perez also acquired 12,254 restricted stock units on June 1, 2024, which vest starting June 1, 2025.
- Additionally, Perez disposed of 10,300 shares of common stock.
- Following these transactions, Perez directly owns 9,730 stock options with an exercise price of $7.34 (expiring 06/10/2029), 8,353 stock options with an exercise price of $14.82 (expiring 08/10/2033), 11,336 restricted stock units, 8,672 new stock options, and 12,254 new restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of options and restricted stock units suggests confidence, but the sale of shares tempers the positive outlook.
Positives
- The acquisition of stock options and restricted stock units by a director could be seen as a positive signal, indicating confidence in the company's future performance.
Negatives
- The disposal of 10,300 shares of common stock by the director could be interpreted negatively, although the acquisition of options and restricted stock units may offset this concern.
Risks
- The value of the stock options is dependent on the future performance of Neogenomics' stock price.
- The vesting of restricted stock units is contingent upon continued service with the company.
Future Outlook
The document does not contain specific forward-looking statements, but the acquisition of stock options and restricted stock units suggests an expectation of future value appreciation.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The transactions may influence shareholder perception of management's confidence in the company.
- Employees may view the granting of restricted stock units as a positive sign.
Key Dates
| Date | Description |
|---|---|
| 06/10/2023 | Date of exercisability for existing stock options with an expiration date of 06/10/2029. |
| 08/10/2024 | Date of exercisability for existing stock options with an expiration date of 08/10/2033 and vesting date for existing restricted stock units. |
| 06/01/2024 | Date of transaction: acquisition of stock options and restricted stock units, and disposition of common stock. |
| 06/01/2025 | Date of exercisability for newly acquired stock options and vesting date for newly acquired restricted stock units. |
| 06/01/2034 | Expiration date for newly acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.